City

Clinical trials near Chicago, United States

Active studies with a listed research site in Chicago, United States.

70active studies

42recruiting now

20countries represented

137largest site network

Current studies

Status and location data reflect the registry snapshot built 2026-09-08. Verify the original record before contacting a site.

Recruiting nowPhase 2

A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

Obesity, OverweightCondition

LY3305677, LY3841136Treatment

Argentina, United States56 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT06143956See eligibility →

Recruiting nowPhase 4

A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)

Psoriatic Arthritis, Overweight or ObesityCondition

TirzepatideTreatment

Puerto Rico, United States55 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT06864026See eligibility →

Recruiting nowPhase 3

A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity

Obesity, Overweight and/or ObesityCondition

PF-08653944, PlaceboTreatment

Brazil, Canada50 locations

PfizerSponsor

Updated 2026-09-04 · NCT07595549See eligibility →

Recruiting nowPhase 3

Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)

Obesity, OverweightCondition

Maridebart cafraglutide, PlaceboTreatment

Australia, Japan87 locations

AmgenSponsor

Updated 2026-09-03 · NCT07684235See eligibility →

Recruiting nowNot applicable

International Rapid-onset Obesity With Hypothalamic Dysfunction, Hypoventilation & Autonomic Dysregulation (ROHHAD) Registry

ROHHAD, Rapid-Onset Obesity With Hypothalamic Dysfunction, Hypoventilation & Autonomic DysregulationCondition

ROHHADTreatment

United States1 locations

Ilya KhaytinSponsor

Updated 2026-09-03 · NCT03135730See eligibility →

Recruiting nowPhase 3

Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes

ObesityCondition

Ribupatide, SemaglutideTreatment

Australia, Bulgaria59 locations

KaileraSponsor

Updated 2026-09-01 · NCT07284979See eligibility →

Recruiting nowNot applicable

BRIDGE & Friends Trial

Obesity & OverweightCondition

Social Network CurriculumTreatment

United States1 locations

University of Illinois at ChicagoSponsor

Updated 2026-09-01 · NCT07798557See eligibility →

Recruiting nowNot applicable

Assess the Effects of Replacing Foods High in Refined Carbohydrates With Avocado on Biomarkers of Inflammation.

Overweight (BMI > 25), Obesity (BMI>30)Condition

Avocado, ControlTreatment

United States2 locations

Midwest Center for Metabolic and Cardiovascular ResearchSponsor

Updated 2026-08-27 · NCT07566325See eligibility →

Recruiting nowPhase 3

A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities

Obesity, OverweightCondition

Orforglipron, PlaceboTreatment

Israel, Italy34 locations

Eli Lilly and CompanySponsor

Updated 2026-08-24 · NCT06672939See eligibility →

Recruiting nowPhase 2

Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL

B-cell Acute Lymphoblastic Leukemia, ObesityCondition

IDEAL2 InterventionTreatment

United States16 locations

Etan OrgelSponsor

Updated 2026-08-19 · NCT05082519See eligibility →

Recruiting nowNot applicable

Digital InteGrated Behavioral treatmeNt for Comorbid obesITy and deprEssion Among Racial and Ethnic Adults Age 50 and Older

Obesity, DepressionCondition

vCare Intervention (6-month active treatment followed by 6-month maintenance), vCare Intervention (active treatment after 6 months)Treatment

United States2 locations

University of Illinois at ChicagoSponsor

Updated 2026-08-18 · NCT06636058See eligibility →

Recruiting nowNot applicable

Role of Adiposomes in Endothelial Dysfunction

Obesity, DiabetesCondition

Exercise trainingTreatment

United States1 locations

University of Illinois at ChicagoSponsor

Updated 2026-08-17 · NCT05199454See eligibility →

Recruiting nowPhase 2

Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder

Opioid Use Disorder, Opioid Use Disorder, ModerateCondition

Tirzepatide, PlaceboTreatment

United States9 locations

T. John Winhusen, PhDSponsor

Updated 2026-08-11 · NCT06651177See eligibility →

Recruiting nowPhase 3

Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)

Obesity, OverweightCondition

Aleniglipron, PlaceboTreatment

United States71 locations

Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure TherapeuticsSponsor

Updated 2026-08-10 · NCT07654361See eligibility →

Recruiting nowNot applicable

Postextubation Use of Noninvasive Respiratory Support in Severely Obese Patients

Obesity, Morbid, Extubation FailureCondition

Noninvasive ventilation alternating with high flow nasal cannula, High flow nasal cannulaTreatment

Mexico, United States5 locations

Rush University Medical CenterSponsor

Updated 2026-08-07 · NCT05918575See eligibility →

Recruiting nowPhase 2

A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight

Overweight, ObesityCondition

Macupatide, EloralintideTreatment

United States40 locations

Eli Lilly and CompanySponsor

Updated 2026-08-06 · NCT07589608See eligibility →

Recruiting nowPhase 2

Efficacy and Safety of Oral KAI-7535 in Adult Participants Living With Obesity or Overweight With at Least 1 Weight-Related Comorbidity

Obesity, OverweightCondition

KAI-7535, PlaceboTreatment

Australia, United States36 locations

KaileraSponsor

Updated 2026-07-28 · NCT07497880See eligibility →

Recruiting nowNot applicable

Functional Improvement in OSA and COPD With a Telehealth LifeStyle and Exercise Intervention

Chronic Obstructive Pulmonary Disease, Obstructive Sleep ApneaCondition

FOCuSEd Integrated Intervention, Enhanced Usual CareTreatment

United States5 locations

Seattle Institute for Biomedical and Clinical ResearchSponsor

Updated 2026-07-22 · NCT06390345See eligibility →

Recruiting nowPhase 2

Multi-Site Trial of Tirzepatide for Smoking Cessation

Smoking Cessation, Smoking BehaviorsCondition

Tirzepatide, PlaceboTreatment

United States4 locations

University of Southern CaliforniaSponsor

Updated 2026-07-17 · NCT07602699See eligibility →

Recruiting nowPhase 2

A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity

ObesityCondition

NNC0662-0419, SemaglutideTreatment

Puerto Rico, United States25 locations

Novo Nordisk A/SSponsor

Updated 2026-07-10 · NCT07639021See eligibility →

Recruiting nowPhase 2

FIM+DASH: Food is Medicine Intervention to Promote Healthy Eating and Blood Pressure Control

Hypertension, Hypertension (HTN)Condition

FIM intervention arm, FIM Usual Care ArmTreatment

United States4 locations

University of Illinois at ChicagoSponsor

Updated 2026-07-10 · NCT07332741See eligibility →

Recruiting nowNot applicable

Better Lifestyle Counseling for African American Women During Pregnancy

Overweight or Obesity, Pregnancy RelatedCondition

Better, Birth PrepTreatment

United States2 locations

University of Illinois at ChicagoSponsor

Updated 2026-07-09 · NCT05234125See eligibility →

Recruiting nowNot applicable

PRImary Care Strategies for Weight Management (PRISM) Study

ObesityCondition

PRISM ProgramTreatment

United States1 locations

Rush University Medical CenterSponsor

Updated 2026-07-09 · NCT07288294See eligibility →

Recruiting nowNot applicable

Adaptive Mechanisms Responsible for Weight Change in Youth With Obesity

Childhood ObesityCondition

Meal replacement and lifestyle modificationTreatment

United States1 locations

Ann & Robert H Lurie Children's Hospital of ChicagoSponsor

Updated 2026-06-02 · NCT05125822See eligibility →

Recruiting nowNot applicable

Conical Forearm and Cylindrical Upper Arm Non-Invasive Blood Pressure (NIBP) Measurements in Pregnant Patients

Hypertension in Pregnancy, HypertensionCondition

Upper Arm Cylindrical Blood Pressure Cuff, Forearm Conical Blood Pressure CuffTreatment

United States1 locations

Northwestern UniversitySponsor

Updated 2026-05-26 · NCT06466161See eligibility →

Recruiting nowNot applicable

Scalable TELeheaLth Cancer CARe: The STELLAR Program to Treat Cancer Risk Behaviors

Obesity, Smoking CessationCondition

multiple behavior change therapyTreatment

United States1 locations

Northwestern UniversitySponsor

Updated 2026-05-08 · NCT05687604See eligibility →

Recruiting nowEarly Phase 1

Randomized Control Trial of Sleeve Gastrectomy With Tirzepatide in Maximizing Weight Loss

Obesity and Obesity-related Medical ConditionsCondition

Mounjaro, Sleeve GastrectomyTreatment

United States1 locations

Nicholas SkertichSponsor

Updated 2026-05-08 · NCT06734273See eligibility →

Recruiting nowNot applicable

Promote Weight Loss in Obese Peripheral Artery Disease (PAD) Patients to Prevent Mobility Loss

Peripheral Artery Disease, Overweight or ObesityCondition

Weight loss, ExerciseTreatment

United States7 locations

Northwestern UniversitySponsor

Updated 2026-05-07 · NCT04228978See eligibility →

Recruiting nowNot applicable

Exogenous and Endogenous Risk Factors for Early-onset Colorectal Cancer

Colorectal Cancer, Early Onset Colorectal CancerCondition

Semi Quantitative Food Frequency Questionnaire (SQFFQ)Treatment

Finland, Germany8 locations

San Raffaele UniversitySponsor

Updated 2026-04-24 · NCT05732623See eligibility →

Recruiting nowPhase 4

PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes

Type2Diabetes, ASCVDCondition

SGLT2 inhibitor, GLP-1 receptor agonistTreatment

United States36 locations

Brigham and Women's HospitalSponsor

Updated 2026-04-13 · NCT05390892See eligibility →

Recruiting nowNot applicable

RemI for Post-Bariatric Surgery Weight Regain

Obesity, Bariatric Surgery CandidateCondition

Acceptance-Based Behavioral InterventionTreatment

United States2 locations

Temple UniversitySponsor

Updated 2026-04-03 · NCT06292936See eligibility →

Recruiting nowNot applicable

Preoperative Weight Loss for Open Abdominal Wall Reconstruction

Abdominal Wall HerniaCondition

Preoperative Weight Management ProgramTreatment

United States2 locations

Benjamin T. MillerSponsor

Updated 2026-03-23 · NCT05925959See eligibility →

Recruiting nowNot applicable

People With Multiple Sclerosis Treated With Ocrelizumab and GLP-1 Agonists

Multiple SclerosisCondition

GLP-1, Ocrelizumab (US)Treatment

United States1 locations

Northwestern UniversitySponsor

Updated 2026-03-17 · NCT07207148See eligibility →

Recruiting nowNot applicable

Predictors of Behavioral Obesity Treatment Outcomes

ObesityCondition

Behavioral weight loss treatmentTreatment

United States1 locations

Rush University Medical CenterSponsor

Updated 2026-03-11 · NCT05326477See eligibility →

Recruiting nowPhase 3

A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756)

Hypothalamic Obesity, Multiple Pituitary Hormone Deficiency Genetic FormCondition

Setmelanotide, PlaceboTreatment

United Kingdom, United States11 locations

Rhythm Pharmaceuticals, Inc.Sponsor

Updated 2026-02-12 · NCT06760546See eligibility →

Recruiting nowNot applicable

Time-restricted Eating Among Pregnant Females With Severe Obesity

Obesity, Morbid, Time Restricted EatingCondition

Time Restricted EatingTreatment

United States1 locations

University of Illinois at ChicagoSponsor

Updated 2026-01-23 · NCT06477120See eligibility →

Recruiting nowPhase 1, Phase 2

A Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway Impairment

Hypothalamic Obesity, Prader-Willi SyndromeCondition

Part A: RM-718 or placebo (matched to specific RM-718 dose cohort), Part B: RM-718 or placebo (matched to specific RM-718 dose cohort)Treatment

United States7 locations

Rhythm Pharmaceuticals, Inc.Sponsor

Updated 2025-12-22 · NCT06239116See eligibility →

Recruiting nowPhase 3

Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation

Overweight or Obesity, Atrial FibrillationCondition

Semaglutide, PlaceboTreatment

United States2 locations

University of ChicagoSponsor

Updated 2025-11-14 · NCT06499857See eligibility →

Recruiting nowNot applicable

Preparing FIM-BCS - A Lifestyle Modification for African-American Breast Cancer Survivors

Hypertension, ObesityCondition

Assigned InterventionsTreatment

United States1 locations

University of Illinois at ChicagoSponsor

Updated 2025-11-10 · NCT06504914See eligibility →

Recruiting nowNot applicable

DNA Methylation and Vascular Function

Obesity, Vascular DysfunctionCondition

Exercise trainingTreatment

United States1 locations

University of Illinois at ChicagoSponsor

Updated 2025-09-15 · NCT03527420See eligibility →

Recruiting nowNot applicable

GI Oxalate Absorption

Bariatric Surgery Candidate, Kidney StoneCondition

Special low-oxalate diet followed by all-day visit to University of Chicago research clinicTreatment

United States1 locations

University of ChicagoSponsor

Updated 2025-08-19 · NCT05356000See eligibility →

Recruiting nowPhase 2, Phase 3

Effectiveness of Alternative Therapies in Maintaining Weight Loss Achieved by GLP-1 Medications Post-Cessation

Longevity, GLP-1Condition

Metformin, RapamycinTreatment

United States1 locations

AgelessRxSponsor

Updated 2025-07-30 · NCT07092618See eligibility →

Opening soonNot applicable

A Trial to Examine the Effects of a Weight Loss Program Emphasizing Protein, Dietary Fiber, and Exercise (30-30-30 Plan)

Overweight , ObesityCondition

30-30-30 PFE Intervention, StandardTreatment

United States3 locations

Midwest Center for Metabolic and Cardiovascular ResearchSponsor

Updated 2026-08-31 · NCT07789769See eligibility →

Opening soonPhase 2

A Study of Weight Loss Intervention With Tirzepatide and Progestin Intrauterine Device to Treat Endometrial Hyperplasia and Grade 1 Endometrial Cancer

Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia, FIGO Grade 1 Endometrial Endometrioid AdenocarcinomaCondition

Medical Device Usage and Evaluation, TirzepatideTreatment

United States3 locations

National Cancer Institute (NCI)Sponsor

Updated 2026-08-26 · NCT07349641See eligibility →

Opening soonPhase 3

A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide

Overweight, ObesityCondition

Zenagamtide, SemaglutideTreatment

United States43 locations

Novo Nordisk A/SSponsor

Updated 2026-08-25 · NCT07668414See eligibility →

Opening soonPhase 3

AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight

Overweight, ObesityCondition

zenagamtide, PlaceboTreatment

United States37 locations

Novo Nordisk A/SSponsor

Updated 2026-08-25 · NCT07720271See eligibility →

Opening soonPhase 1

Impact of Using a GLP1 on Treatment Related Side Effects of Lung Cancer Patients Receiving Lorlatinib

Lung CancerCondition

TirzepatideTreatment

United States1 locations

University of ChicagoSponsor

Updated 2026-08-24 · NCT07782359See eligibility →

Active, not recruitingNot applicable

The PIVOT Trial: Project on EHR-Integrated Lifestyle Interventions for Adults Aged Fifty and Older

CARDIOMETABOLIC CONDITIONS, ObesityCondition

Base intervention, Augmented InterventionTreatment

United States3 locations

University of Illinois at ChicagoSponsor

Updated 2026-08-31 · NCT05654142See eligibility →

Active, not recruitingNot applicable

Pulses Consumption and Its Role in Managing Systemic Inflammation, Insulin Sensitivity and Gut Microbiome in Human

Insulin Sensitivity, Overweight or ObesityCondition

Control, Black beanTreatment

United States1 locations

Clinical Nutrition Research Center, Illinois Institute of TechnologySponsor

Updated 2026-08-28 · NCT04267705See eligibility →

Active, not recruitingPhase 2

Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2)

Overweight, Type 2 DiabetesCondition

Petrelintide, PlaceboTreatment

United States48 locations

Zealand PharmaSponsor

Updated 2026-08-21 · NCT06926842See eligibility →

Active, not recruitingPhase 3

A Trial of Setmelanotide in Acquired Hypothalamic Obesity

Hypothalamic ObesityCondition

Setmelanotide, PlaceboTreatment

Canada, Germany28 locations

Rhythm Pharmaceuticals, Inc.Sponsor

Updated 2026-08-10 · NCT05774756See eligibility →

Active, not recruitingPhase 3

A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term

ObesityCondition

CagriSema (Cagrilintide B and Semaglutide I), Placebo matched to CagriSema (Cagrilintide B and Semaglutide I)Treatment

United States46 locations

Novo Nordisk A/SSponsor

Updated 2026-07-24 · NCT07011667See eligibility →

Active, not recruitingNot applicable

Time-restricted Eating Versus Daily Continuous Calorie Restriction on Body Weight and Colorectal Cancer Risk Markers

Time Restricted Eating, ObesityCondition

Time restricted eating, Calorie RestrictionTreatment

United States1 locations

University of Illinois at ChicagoSponsor

Updated 2026-07-21 · NCT05114798See eligibility →

Active, not recruitingPhase 3

A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity

ObesityCondition

Retatrutide, TirzepatideTreatment

Argentina, Germany65 locations

Eli Lilly and CompanySponsor

Updated 2026-07-20 · NCT06662383See eligibility →

Active, not recruitingPhase 2

A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes

Obesity, OverweightCondition

LY3841136, TirzepatideTreatment

Argentina, United States52 locations

Eli Lilly and CompanySponsor

Updated 2026-07-17 · NCT06603571See eligibility →

Active, not recruitingNot applicable

Virtual Diabetes Group Visits Across Health Systems

T2DM (Type 2 Diabetes Mellitus), HypertensionCondition

Virtual Group VisitTreatment

United States2 locations

University of ChicagoSponsor

Updated 2026-07-08 · NCT06094491See eligibility →

Active, not recruitingNot applicable

Project VIBE: Virtual Intervention for Binge Eating in Adolescents

Obesity, Binge-Eating DisorderCondition

Feasibility/Efficacy TestingTreatment

United States2 locations

University of PittsburghSponsor

Updated 2026-07-08 · NCT06819813See eligibility →

Active, not recruitingPhase 2

A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight

Obesity, OverweightCondition

Bimagrumab, TirzepatideTreatment

United States12 locations

Eli Lilly and CompanySponsor

Updated 2026-05-26 · NCT06643728See eligibility →

Active, not recruitingNot applicable

Elements Vital to Treat Obesity Study

ObesityCondition

Smartphone App Participants (APP), Diabetes Prevention Program Participants (DPP)Treatment

United States1 locations

Northwestern UniversitySponsor

Updated 2026-05-06 · NCT04708769See eligibility →

Active, not recruitingPhase 3

VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)

Weight LossCondition

VK2735Treatment

Puerto Rico, United States127 locations

Viking Therapeutics, Inc.Sponsor

Updated 2026-04-07 · NCT07104383See eligibility →

This page shows the first 60 studies. Use the full search to filter all matches.

How current is this page?

The page is rebuilt from the public registry feed. Each trial card shows the registry update date. Recruitment can still change between builds.

Does appearing here mean I qualify?

No. These pages are discovery indexes. Only a study team can confirm eligibility after reviewing the complete protocol criteria.

Clinical trials near Chicago, United States

Current studies

Related cities